Prelude Therapeutics announced on October 18, 2025 that Katina Dorton, J.D., MBA, will join the company’s Board of Directors effective October 17, 2025. The appointment replaces current board member Mardi C. Dier, who will resign on the same date, and will also succeed Dier as Chair of the Audit Committee.
Dorton brings more than 30 years of experience in healthcare and life sciences, having served as Chief Financial Officer at NodThera and as the finance leader who built and led the finance organization for Repare Therapeutics, preparing the company for an IPO and raising over $82 million in crossover funding. She has also held senior finance roles at AVROBIO and Immatics N.V., and has served on the boards of Mallinckrodt Pharmaceuticals, Fulcrum Therapeutics, TScan Therapeutics, and Sonoma Biotherapeutics.
The addition of Dorton is a strategic governance move that strengthens Prelude’s financial oversight and capital‑raising capabilities. Her track record in preparing companies for public markets and securing significant funding aligns with Prelude’s urgent need to extend its cash runway and pursue future clinical milestones. This board change is therefore a material event that can positively influence investor confidence and the company’s ability to secure financing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.